Increasing the infliximab dose is beneficial in Crohn's disease patients who responded to a lower dose and relapsed

Digestion

Volumn 72, Issue 2-3, 2005, Pages 124-128

  Menachem, Yoram ^a   Avidan, Benjamin ^a   Lavy, Alexandra ^b   Lang, Alon ^a   Bardan, Eytan ^a   Fidder, Herma ^a   Bar Meir, Simon ^a   Chowers, Yehuda ^a  

^a SHEBA MEDICAL CENTER   (Israel)

^b BNAI ZION MEDICAL CENTER   (Israel)

Author keywords

CD, inflammatory and fistulizing; Crohn's disease; Infliximab; Relapse in CD patients

Indexed keywords

INFLIXIMAB;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; COLITIS; COLON FISTULA; CROHN DISEASE; DOSE RESPONSE; DRUG EFFICACY; FEMALE; HUMAN; MAINTENANCE THERAPY; MALE; PRIORITY JOURNAL; RELAPSE; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL; CROHN DISEASE; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; MALE; MIDDLE AGED; RECURRENCE; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME;

EID: 27144507495     PISSN: 00122823     EISSN: None     Source Type: Journal    
DOI: 10.1159/000088367     Document Type: Article

References (11)

1. Podolsky DK: Inflammatory bowel disease. N Engl J Med 2002;347:417-427.
2. Targan SR, Hanauer SB, van Deventer SJH, et al: A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. N Engl J Med 1997;337:1029-1035.
3. Hanauer SB, Feagan BG, Lichtenstein GR, et al: Maintenance infliximab for Crohn's disease: The ACCENT I randomized trial. Lancet 2002;359:1541-1549.
4. Baert F, Noman M, Vermeire S, et al: Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003;348:601-608.
5. McBabe RP, Woody J, van Deventer SJH, et al: A multicenter trial of cA2 anti-TNF chimeric monoclonal antibody in patients with active Crohn's disease. Gastroenterology 1996;110:A962.
6. Wagner C, Mace K, DeWoody K, et al: Infliximab treatment benefits correlate with pharmacodynamic parameters in Crohn's disease patients. Digestion 1998;59(suppl 3):124-125.
7. Rutgeerts P, D'Haens G, Targan S, et al: Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 1999;117:761-769.
8. Harvey RF, Bradshaw JM: A simple index of Crohn's-disease activity. Lancet 1980;1:514.
9. Rutgeerts P, Feagan BG, Lichtenstein GR, et al: Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 2004;126:402-413.
10. Stephens MC, Shepanski MA, Mamula P, et al: Safety and steroid-sparing experience using infliximab for Crohn's disease at a pediatric inflammatory bowel disease center. Am J Gastroenterol 2003;98:104-111.
11. Farrell RJ, Alshali M, Falchuk KR: Human anti-chimeric antibody levels correlate with lack of response and infusion reactions following infliximab therapy. Gastroenterology 2001;120(suppl 1):P83.